Tatiana Novobrantseva MS, PhD

Tatiana Novobrantseva is a Co-Founder and has served as Chief Scientific Officer of Verseau since March 2019 and prior to her current role, served as Head of Research and Development. Before co-founding Verseau, she consulted for multiple companies on immunological aspects of drug development across different stages and therapeutic modalities in a variety of autoimmune, cancer and rare disease indications.

Tatiana is an inventor on more than 22 patents and an author on more than 37 peer-reviewed manuscripts. Tatiana completed her Ph.D. with Dr. Klaus Rajewsky at the University of Cologne in Germany, focusing on B cell development and function. She holds a diploma of engineer-physicist and an M.S. in molecular biology from Moscow Institute of Physics and Technology.